The DOI matches its Crossref record; 31 of the 31 references it cites were found in a registry or an index.
Predictors of Clinical Improvement in Rituximab‐Treated Refractory Adult and Juvenile Dermatomyositis and Adult Polymyositis
Open accessAbstract
Objective: To identify the clinical and laboratory predictors of clinical improvement in a cohort of myositis patients treated with rituximab. Methods: We analyzed data for 195 patients with myositis (75 with adult polymyositis [PM], 72 with adult dermatomyositis [DM], and 48 with juvenile DM) in the Rituximab in Myositis trial. Clinical improvement was defined as 20% improvement in at least 3 of the following 6 core set measures of disease activity: physician's and patient's/parent's global assessment of disease activity, manual muscle testing, physical function, muscle enzymes, and extramuscular disease activity. We analyzed the association of the following baseline variables with improvement: myositis clinical subgroup, demographics, myositis damage, clinical and laboratory parameters, core set measures, rituximab treatment, and myositis autoantibodies (antisynthetase, anti–Mi‐2, anti–signal recognition particle, anti–transcription intermediary factor 1γ [TIF‐1γ], anti‐MJ, other autoantibodies, and no autoantibodies). All measures were univariately assessed for association with improvement using time‐to‐event analyses. A multivariable time‐dependent proportional hazards model was used to evaluate the association of individual predictive factors with improvement. Results: In the final multivariable model, the presence of an antisynthetase, primarily anti–Jo‐1 (hazard ratio [HR] 3.08, P < 0.01), anti–Mi‐2 (HR 2.5, P < 0.01), or other autoantibody (HR 1.4, P = 0.14) predicted a shorter time to improvement compared to the absence of autoantibodies. A lower physician's global assessment of damage (HR 2.32, P = 0.02) and juvenile DM (versus adult myositis) (HR 2.45, P = 0.01) also predicted improvement. Unlike autoantibody status, the predictive effect of physician's global assessment of damage and juvenile DM diminished by week 20. Rituximab treatment did not affect these associations. Conclusion: Our findings indicate that the presence of antisynthetase and anti–Mi‐2 autoantibodies, juvenile DM subset, and lower disease damage strongly predict clinical improvement in patients with refractory myositis.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Polymyositis and Dermatomyositis: (First of Two Parts)
Bohan, A., & Peter, J. B. (1975) · New England Journal of Medicine · doi:10.1056/nejm197502132920706 · Cited by 5,059
Polymyositis and Dermatomyositis: (Second of Two Parts)
Bohan, A., & Peter, J. B. (1975) · New England Journal of Medicine · doi:10.1056/nejm197502202920807 · Cited by 2,447
Dalakas, M. C., Illa, I., Dambrosia, J. M., Soueidan, S. A., Stein, D. P., Otero, C., Dinsmore, S. T., & McCrosky, S. (1993) · New England Journal of Medicine · doi:10.1056/nejm199312303292704 · Cited by 1,136
Love, L. A., Leff, R. L., Fraser, D. D., Targoff, I. N., Dalakas, M., Plotz, P. H., & Miller, F. W. (1991) · Medicine · doi:10.1097/00005792-199111000-00002 · Cited by 969
Self-citationOddis, C. V., Reed, A. M., Aggarwal, R., Rider, L. G., Ascherman, D. P., Levesque, M. C., Barohn, R. J., Feldman, B. M., Harris‐Love, M. O., Koontz, D. C., et al. (2013) · Arthritis & Rheumatism · doi:10.1002/art.37754 · Cited by 701
Self-citationTwo Distinct Cytokines Released from a Human Aminoacyl-tRNA Synthetase
Wakasugi, K., & Schimmel, P. (1999) · Science · doi:10.1126/science.284.5411.147 · Cited by 504
Hamaguchi, Y., Kuwana, M., Hoshino, K., Hasegawa, M., Kaji, K., Matsushita, T., Komura, K., Nakamura, M., Kodera, M., Suga, N., et al. (2011) · Archives of Dermatology · doi:10.1001/archdermatol.2011.52 · Cited by 333
Polymyositis: An overdiagnosed entity
van der Meulen, M. F. G., Bronner, I. M., Hoogendijk, J. E., Burger, H., van Venrooij, W. J., Voskuyl, A. E., Dinant, H. J., Linssen, W. H. J. P., Wokke, J. H. J., & de Visser, M. (2003) · Neurology · doi:10.1212/wnl.61.3.316 · Cited by 332
Miller, F. W. (2001) · Rheumatology · doi:10.1093/rheumatology/40.11.1262 · Cited by 332
Self-citationJoffe, M. M., Love, L. A., Leff, R. L., Fraser, D. D., Targoff, I. N., Hicks, J. E., Plotz, P. H., & Miller, F. W. (1993) · The American Journal of Medicine · doi:10.1016/0002-9343(93)90148-i · Cited by 309
Self-citationAggarwal, R., Cassidy, E., Fertig, N., Koontz, D. C., Lucas, M., Ascherman, D. P., & Oddis, C. V. (2014) · Annals of the Rheumatic Diseases · doi:10.1136/annrheumdis-2012-201800 · Cited by 301
Self-citationMarié, I., HACHULLA, E., Hatron, P., Hellot, M., Levesque, H., Devulder, B., & Courtois, H. (2001) · PubMed · Cited by 287
Ravelli, A., Trail, L., Ferrari, C., Ruperto, N., Pistorio, A., Pilkington, C., Maillard, S., Oliveira, S. K., Sztajnbok, F., Cuttica, R., et al. (2010) · Arthritis Care & Research · doi:10.1002/acr.20015 · Cited by 279
Howard, O. M. Z., Dong, H. F., Yang, D., Raben, N., Nagaraju, K., Rosen, A., Casciola-Rosen, L., Härtlein, M., Kron, M., Yang, D., et al. (2002) · The Journal of Experimental Medicine · doi:10.1084/jem.20020186 · Cited by 279
Rider, L. G., Koziol, D., Giannini, E. H., Jain, M. S., Smith, M. R., Whitney‐Mahoney, K., Feldman, B. M., Wright, S. J., Lindsley, C. B., Pachman, L. M., et al. (2010) · Arthritis Care & Research · doi:10.1002/acr.20035 · Cited by 277
Self-citationYoshida, S., Akizuki, M., Mimori, T., et al. (1983) · Arthritis & Rheumatism · doi:10.1002/art.1780260505 · Cited by 232
International consensus on preliminary definitions of improvement in adult and juvenile myositis
Rider, L. G., Giannini, E. H., Brunner, H. I., Ruperto, N., James‐Newton, L., Reed, A. M., Lachenbruch, P. A., & Miller, F. W. (2004) · Arthritis & Rheumatism · doi:10.1002/art.20349 · Cited by 229
Self-citationLong-term outcome in polymyositis and dermatomyositis
Bronner, I. M., van der Meulen, M. F. G., de Visser, M., Kalmijn, S., van Venrooij, W. J., Voskuyl, A. E., Dinant, H. J., Linssen, W. H. J. P., Wokke, J. H. J., & Hoogendijk, J. E. (2006) · Annals of the Rheumatic Diseases · doi:10.1136/ard.2005.045690 · Cited by 215
Influence of Age on Characteristics of Polymyositis and Dermatomyositis in Adults
Marie, I., Hatron, P.-Y., Levesque, H., Hachulla, E., Hellot, M.-F., Michon-Pasturel, U., Courtois, H., & Devulder, B. (1999) · Medicine · doi:10.1097/00005792-199905000-00001 · Cited by 187
Defining Clinical Improvement in Adult and Juvenile Myositis.
Rider, L. G., Giannini, E. H., Harris‐Love, M. O., Joe, G. O., Isenberg, D. A., Pilkington, C., Lachenbruch, P. A., & Miller, F. W. (2003) · PubMed · Cited by 183
Self-citationPrognosis and mortality of polymyositis and dermatomyositis patients
Airio, A., Kautiainen, H., & Hakala, M. (2006) · Clinical Rheumatology · doi:10.1007/s10067-005-1164-z · Cited by 181
A randomized, pilot trial of etanercept in dermatomyositis
The Muscle Study Group (2011) · Annals of Neurology · doi:10.1002/ana.22477 · Cited by 167
Self-citationRider, L. G., Lachenbruch, P. A., Monroe, J. B., Ravelli, A., Cabalar, I., Feldman, B. M., Villalba, M. L., Myones, B. L., Pachman, L. M., Rennebohm, R. M., et al. (2009) · Arthritis & Rheumatism · doi:10.1002/art.24904 · Cited by 158
Self-citationWakasugi, K., & SCHIMMEL, P. R. (1999) · Journal of Biological Chemistry · doi:10.1074/jbc.274.33.23155 · Cited by 149
Hengstman, G. J. D., Egberts, W. T. M. V., Seelig, H. P., Lundberg, I. E., Moutsopoulos, H. Μ., Doria, A., Mosca, M., Vencovský, J., VENROOIJ, W. J. V., & van Engelen, B. G. M. (2006) · Annals of the Rheumatic Diseases · doi:10.1136/ard.2005.040717 · Cited by 140
Miller, F. W., Twitty, S., Biswas, T., & Plotz, P. H. (1990) · Journal of Clinical Investigation · doi:10.1172/jci114461 · Cited by 129
Self-citationReliability and validity of the myositis disease activity assessment tool
Sultan, S. M., Allen, E., Oddis, C. V., et al. (2008) · Arthritis & Rheumatism · doi:10.1002/art.23963 · Cited by 122
Self-citationLong-term outcome in patients with juvenile dermatomyositis: a cross-sectional follow-up study
Mathiesen, P. R., Hegaard, H. K., Herlin, T., Zak, M., Pedersen, F. K., & Nielsen, S. (2011) · Scandinavian Journal of Rheumatology · doi:10.3109/03009742.2011.608376 · Cited by 98
Sanner, H., Kirkhus, E., Merckoll, E., Tollisen, A., Røisland, M., Lie, B. A., Taraldsrud, E., Gran, J. T., & Flatø, B. (2010) · Arthritis Care & Research · doi:10.1002/acr.20203 · Cited by 76
Chiu, Y. E., & Co, D. O. (2011) · Pediatric Dermatology · doi:10.1111/j.1525-1470.2011.01501.x · Cited by 40
The role of jo-1 in the immunopathogenesis of polymyositis: Current hypotheses
Ascherman, D. P. (2003) · Current Rheumatology Reports · doi:10.1007/s11926-003-0052-2 · Cited by 30
Self-citation
Cited by
Myositis‐specific autoantibodies: an important tool to support diagnosis of myositis
Betteridge, Z., & McHugh, N. (2016) · Journal of Internal Medicine · doi:10.1111/joim.12451 · Cited by 1,056
Dalakas, M. C. (2015) · New England Journal of Medicine · doi:10.1056/nejmra1402225 · Cited by 790
Idiopathic inflammatory myopathies
Lundberg, I. E., Fujimoto, M., Vencovsky, J., Aggarwal, R., Holmqvist, M., Christopher-Stine, L., Mammen, A. L., & Miller, F. W. (2021) · Nature Reviews Disease Primers · doi:10.1038/s41572-021-00321-x · Cited by 703
Self-citationClassification and management of adult inflammatory myopathies
Selva-O'Callaghan, A., Pinal-Fernandez, I., Trallero-Araguás, E., Milisenda, J. C., Grau-Junyent, J. M., & Mammen, A. L. (2018) · The Lancet Neurology · doi:10.1016/s1474-4422(18)30254-0 · Cited by 430
Doyle, T. J., Dhillon, N., Madan, R., Cabral, F., Fletcher, E. A., Koontz, D. C., Aggarwal, R., Osorio, J. C., Rosas, I. O., Oddis, C. V., et al. (2018) · The Journal of Rheumatology · doi:10.3899/jrheum.170541 · Cited by 102
Self-citation
Metadata
- Authors
- Aggarwal, R., Bandos, A., Reed, A. M., Ascherman, D. P., Barohn, R. J., Feldman, B. M., Miller, F. W., Rider, L. G., Harris‐Love, M. O., Levesque, M. C., the RIM Study Group, & Oddis, C. V.
- Venue
- Arthritis & Rheumatology
- Publisher
- Wiley
- Published
- 2014-02-25
- Volume
- 66
- Issue
- 3
- Pages
- 740-749
- ISSN
- 2326-5191 (ISSN-L)
- 2326-5205
- OpenAlex
- W2125816072
- Cited by
- 281
- References
- 31
- FWCI
- 11.89
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.